[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-332476-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-332476-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","mirnas-as-potential-biomarkers-in-early-breast-cancer-detection-a-systematic-review","MiRNAs as potential biomarkers in early breast cancer detection - a systematic review","","Breast cancer remains a major global health challenge, and current early-detection approaches such as mammography and core needle biopsy have important limitations in sensitivity, specificity, and diagnostic certainty across ADH, DCIS, and IDC. This systematic review consolidates evidence that microRNAs (miRNAs), small non-coding regulators with abnormal expression in breast cancer tissue and serum/plasma, may improve non-invasive detection and differentiation of early lesions. By modulating proto-oncogenes or tumor suppressor genes at the post-transcriptional level, miRNAs like miR-21, miR-155, and miR-200c could support risk prediction and reduce reliance on invasive procedures.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/mirnas-as-potential-biomarkers-in-early-breast-cancer-detection-a-systematic-review/332476/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/mirnas-as-potential-biomarkers-in-early-breast-cancer-detection-a-systematic-review/332476.png","ImageObject",300,407,{"name":42,"@type":43},"Levi","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-06","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is early breast cancer detection clinically important?","Question",{"text":63,"@type":64},"Early detection improves the likelihood of successful treatment and more favorable patient outcomes. It also supports earlier diagnosis of preneoplastic changes that precede invasive disease.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What role do miRNAs play in early breast cancer development?",{"text":68,"@type":64},"MiRNAs are small non-coding RNAs that show abnormal expression in tissue and serum/plasma. They regulate proto-oncogenes or tumor suppressor genes at the post-transcriptional level, influencing key processes such as proliferation and apoptosis.",{"name":70,"@type":61,"acceptedAnswer":71},"How can miRNAs help distinguish between early breast lesions?",{"text":72,"@type":64},"Specific miRNAs may differentiate normal tissue from various lesion stages, including ADH, DCIS, and IDC. Serum and plasma miRNAs provide a non-invasive route to distinguish breast cancer stages.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},332476,1790144056,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":102,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":4},7971461740909,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","JOURNAL of MEDICINE and LIFE  \nJML | REVIEW  \nMiRNAs as potential biomarkers in early breast cancer detection: a systematic review  \nAna-Maria Mihai1*, Laura Maria Ianculescu1, Nicolae Suciu1,2  \n1. Polizu Department, Alessandrescu-Rusescu National Institute for Mother and Child Health, Bucharest, Romania  \n2. Carol Davila University of Medicine and Pharmacy, Bucharest, Romania  \n* Corresponding author DOI  \nAna-Maria Mihai 10.25122/jml-2024-0322  \nPolizu Department,  \nAlessandrescu-Rusescu National Institute for Mother and Child Health, Dates  \nBucharest, Romania Received: 25 May 2024  \nE-mail: [anamaria.mihai@drd.umfcd.ro](anamaria.mihai@drd.umfcd.ro) Accepted: 31 May 2024  \nABSTRACT  \nBreast cancer remains a significant global health challenge, with high incidence and mortality rates. While mammography has contributed to declining mortality, its limitations in sensitivity and specificity for early detection, particularly in distinguishing between pure atypical ductal hyperplasia (ADH), ductal carcinoma in situ (DCIS), and invasive ductal carcinoma (IDC), highlight the need for more precise tools. Even with core needle biopsy (CNB), conclusive diagnoses often require surgical excision. This underscores the urgency for non-invasive biomarkers to improve early detection and differentiation, potentially reducing invasive procedures. Recent research has shifted focus from mRNAto microRNAs (miRNAs) as promising biomarkers for breast cancer screening. These small non-coding RNAs, which exhibit abnormal expression patterns in breast cancer patients' tissue and serum/plasma, play crucial roles in early breast cancer development by modulating proto-oncogenes or tumor suppressor genes at the post-transcriptional level. Notably, miRNAs such as miR-21, miR-155, and miR-200c are key regulators of cell proliferation and apoptosis, with the potential to distinguish between normal tissue and various stages of breast lesions, including ADH, DCIS, and IDC. Additionally, miRNAs in serum and plasma offer a non-invasive method to differentiate breast cancer stages. This review aims to consolidate current knowledge on early breast lesions and explore the potential of miRNAsas biomarkers for early breast cancer detection, which could enhance risk prediction and reduce reliance on invasive diagnostic procedures.  \nKEYWORDS: breast cancer, early detection, biomarkers, miRNAs  \nINTRODUCTION  \nWith the increasing emphasis on early detection and the widespread use of mammography, there has been a significant rise in the identification of non-malignant breast lesions, such as atypical ductal hyperplasia (ADH), ductal carcinoma in situ (DCIS), atypical lobular hyperplasia (ALH), and lobular carcinoma in situ (LCIS) . These lesions are increasingly recognized as substantial risk factors for the subsequent development of invasive breast carcinoma. The traditional linear progression model of ductal breast cancer, which is the most prevalent form of breast cancer, postulates a stepwise transition: beginning from normal breast epithelial cells to ductal hyperplasia, then to atypical ductal hyperplasia (ADH), progressing to ductal carcinoma in situ (DCIS), and ultimately leading to invasive ductal carcinoma (IDC) [1] . This linear progression model is supported by extensive genomic and immunohistochemical evidence, demonstrating unique molecular and cellular characteristics at each stage of disease development [2]. However, while this model has been instrumen-  \ntal in guiding clinical practice, it oversimplifies the intricate biological processes underlying breast cancer evolution. Emerging research in molecular genetics and immunohistochemistry has begun to unravel the complexity of breast cancer pathogenesis, revealing that the progression to invasive cancer is not strictly linear. Instead, it involves multiple, potentially divergent pathways that can lead to the development of invasive carcinoma. Recent advances have identified several alternative pathways","cbCainBl5KUUQgTr","https://ap.wps.com/l/cbCainBl5KUUQgTr","pdf",188149,"English","# Abstract\n# Introduction\n## Clinical background: non-malignant lesions and risk\n## Limitations of linear progression models\n## Heterogeneity and alternative molecular pathways","[{\"question\":\"Why is early breast cancer detection clinically important?\",\"answer\":\"Early detection improves the likelihood of successful treatment and more favorable patient outcomes. It also supports earlier diagnosis of preneoplastic changes that precede invasive disease.\"},{\"question\":\"What role do miRNAs play in early breast cancer development?\",\"answer\":\"MiRNAs are small non-coding RNAs that show abnormal expression in tissue and serum/plasma. They regulate proto-oncogenes or tumor suppressor genes at the post-transcriptional level, influencing key processes such as proliferation and apoptosis.\"},{\"question\":\"How can miRNAs help distinguish between early breast lesions?\",\"answer\":\"Specific miRNAs may differentiate normal tissue from various lesion stages, including ADH, DCIS, and IDC. Serum and plasma miRNAs provide a non-invasive route to distinguish breast cancer stages.\"}]","MiRNAs as potential biomarkers in early breast cancer detection - a systematic review | PDF",1789998384,15]